Preventive strategies in chronic liver disease: Part I. Alcohol, vaccines, toxic medications and supplements, diet and exercise

American Family Physician

Volumn 64, Issue 9, 2001, Pages 1555-1560

  Riley III, Thomas R ^a,b   Bhatti, Ahsan M ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; AMFEBUTAMONE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; CHLORPROMAZINE; ETRETINATE; FLUCONAZOLE; HALOTHANE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HERBACEOUS AGENT; HORMONE; ITRACONAZOLE; KETOCONAZOLE; METHOTREXATE; NICOTINIC ACID; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYTOIN; PIOGLITAZONE; PSYCHOTROPIC AGENT; RETINOID; TAMOXIFEN CITRATE; UNINDEXED DRUG; VALPROIC ACID;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; CHRONIC LIVER DISEASE; DIET; EXERCISE; FATTY LIVER; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER TOXICITY; REVIEW; SILYBUM MARIANUM; UNITED STATES; VACCINATION;

ALCOHOL DRINKING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; DIET; EXERCISE; FAMILY PRACTICE; HEPATITIS C; HEPATITIS, TOXIC; HUMANS; LIVER DISEASES;

EID: 0035503159     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Deaths: Final data for 1998
2. The natural history of community-acquired hepatitis C in the United States
3. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up
4. Epidemiology of hepatitis C
5. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy
6. Combination treatment with interferon and ribavirin for chronic hepatitis C
7. Hepatitis B
8. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis
9. Prognosis and life expectancy in chronic liver disease
10. Alcohol consumption and mortality among middle-aged and elderly U.S. adults
11. Effects of ethanol on the liver
12. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis
13. Hepatitis C and alcohol
14. Alcoholic liver disease: Proposed recommendations for the American College of Gastroenterology
15. Patients with alcohol problems
16. Fulminant hepatitis A in chronic HBV carrier
17. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?
18. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
19. The public's health unprotected. Reversing a decade of underutilization of hepatitis-B vaccine
20. Hepatitis A vaccine
21. Adult immunizations
22. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease
23. Drug-induced hepatotoxicity
24. Prevention and treatment of drug-induced liver disease
25. Toxicity of nonsteroidal anti-inflammatory drugs. An overview of the epidemiological evidence
26. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: A case series
27. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure
28. Milk thistle (Silybum marianum) for the therapy of liver disease
29. Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders
30. Iron overload in patients with chronic viral hepatitis: How common is it?
31. Measurements of iron status in patients with chronic hepatitis
32. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C
33. Response to interferon alpha therapy is influenced by the iron content of the liver
34. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron
35. Influence of low iron diet on the efficacy of interferon therapy in patients with chronic liver disease
36. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study
37. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
38. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
39. Relationship between liver biochemical tests and dietary intake in patients with liver disease